Literature DB >> 24900518

JAK Kinase Inhibitors as Possible Treatment for Myeloproliferative Disorders and Cancer: Patent Highlight.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2012        PMID： 24900518      PMCID： PMC4025656          DOI： 10.1021/ml300155w

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  The many faces of Janus kinase.

Authors:  Matthew M Seavey; Pawel Dobrzanski
Journal:  Biochem Pharmacol       Date:  2011-12-24       Impact factor: 5.858

Review 2.  The use of structural biology in Janus kinase targeted drug discovery.

Authors:  Nilda L Alicea-Velázquez; Titus J Boggon
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

Review 3.  New JAK2 inhibitors for myeloproliferative neoplasms.

Authors:  Alfonso Quintás-Cardama; Srdan Verstovsek
Journal:  Expert Opin Investig Drugs       Date:  2011-04-27       Impact factor: 6.206

Review 4.  JAK-STAT signaling in hepatic fibrosis.

Authors:  Markus Mair; Leander Blaas; Christoph H Österreicher; Emilio Casanova; Robert Eferl
Journal:  Front Biosci (Landmark Ed)       Date:  2011-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.